Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 5036 results found since Jan 2013.
Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review
CONCLUSIONS: The use of SC daratumumab, rituximab, and trastuzumab in patients with cancer reduces direct and indirect costs and adverse events compared to IV use. Patients prefer the SC administration, perceiving more comfort, and less pain at the administration site.PMID:37665685 | DOI:10.1080/14737167.2023.2249232
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 4, 2023 Category: Health Management Authors: Ana Parra Claudia Hern ández Laura Prieto-Pinto Source Type: research
Multiple sclerosis is associated with worse COVID-19 outcomes compared to the general population: A population-based study
CONCLUSION: This study revealed higher odds of hospitalization and mortality due to COVID-19 among PLWMS in comparison to age- and sex-matched controls from the general population. Nevertheless, it remains unclear whether the elevated odds are directly associated with MS itself or if they are influenced by factors such as rituximab using, comorbidity, and disease severity.PMID:37659351 | DOI:10.1016/j.msard.2023.104947
Source: Cancer Control - September 2, 2023 Category: Cancer & Oncology Authors: Mahdi Barzegar Setayesh Sindarreh Amirreza Manteghinejad Omid Mirmosayyeb Shahrbanoo Mazaheri Maryam Rahimi Shaghayegh Haghjooy Javanmard Vahid Shaygannejad Maryam Nasirian Source Type: research
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia
J Cell Mol Med. 2023 Aug 31. doi: 10.1111/jcmm.17868. Online ahead of print.ABSTRACTMantle-cell lymphoma (MCL) is a B-cell non-Hodgkin Lymphoma (NHL) with a poor prognosis, at high risk of relapse after conventional treatment. MCL-associated tumour microenvironment (TME) is characterized by M2-like tumour-associated macrophages (TAMs), able to interact with cancer cells, providing tumour survival and resistance to immuno-chemotherapy. Likewise, monocyte-derived nurse-like cells (NLCs) present M2-like profile and provide proliferation signals to chronic lymphocytic leukaemia (CLL), a B-cell malignancy sharing with MCL some ...
Source: Molecular Medicine - September 1, 2023 Category: Molecular Biology Authors: Andrea Aroldi Mario Mauri Daniele Ramazzotti Matteo Villa Federica Malighetti Valentina Crippa Federica Cocito Chiara Borella Elisa Bossi Carolina Steidl Chiara Scollo Claudia Voena Roberto Chiarle Luca Mologni Rocco Piazza Carlo Gambacorti-Passerini Source Type: research
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan
CONCLUSIONS: This study suggests that Pola + R-CHP is a cost-effective treatment for previously untreated DLBCL in Japan under the public health insurance system.PMID:37656225 | DOI:10.1080/13696998.2023.2254162
Source: Journal of Medical Economics - September 1, 2023 Category: Health Management Authors: Takashi Mizuoka Hiroyuki Sakamaki Shigeo Fuji Shota Saito Tatsunori Murata Shinya Ohno Naoki Inubashiri Tomoha Oshima Kazuhito Yamamoto Source Type: research
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia
J Cell Mol Med. 2023 Aug 31. doi: 10.1111/jcmm.17868. Online ahead of print.ABSTRACTMantle-cell lymphoma (MCL) is a B-cell non-Hodgkin Lymphoma (NHL) with a poor prognosis, at high risk of relapse after conventional treatment. MCL-associated tumour microenvironment (TME) is characterized by M2-like tumour-associated macrophages (TAMs), able to interact with cancer cells, providing tumour survival and resistance to immuno-chemotherapy. Likewise, monocyte-derived nurse-like cells (NLCs) present M2-like profile and provide proliferation signals to chronic lymphocytic leukaemia (CLL), a B-cell malignancy sharing with MCL some ...
Source: J Cell Mol Med - September 1, 2023 Category: Molecular Biology Authors: Andrea Aroldi Mario Mauri Daniele Ramazzotti Matteo Villa Federica Malighetti Valentina Crippa Federica Cocito Chiara Borella Elisa Bossi Carolina Steidl Chiara Scollo Claudia Voena Roberto Chiarle Luca Mologni Rocco Piazza Carlo Gambacorti-Passerini Source Type: research
Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature
CONCLUSIONS AND IMPORTANCE: ME is a rare complication after Rituximab infusions and very few cases are reported in the literature. Usually, ME occurs a few weeks after systemic administration and is probably related to a local release of cytokines. It resolves with oral, subtenon or intravitreal steroids. Our case is the first showing that IDI is a safe and effective treatment in ME secondary to Rituximab. Rituximab is not required to be discontinued if treatment for ME is started.PMID:37644808 | DOI:10.1177/11206721231199120
Source: European Journal of Ophthalmology - August 30, 2023 Category: Opthalmology Authors: Martina Maceroni Angelo Maria Minnella Source Type: research
Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4068 patients
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283446. Online ahead of print.ABSTRACTPrimary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathologic entity. Currently, there is a paucity of randomized prospective data to inform on optimal frontline chemoimmunotherapy (CIT) and use of consolidative mediastinal radiation (RT). To assess if distinct CIT approaches are associated with disparate survival outcomes, we performed a systematic review and meta-analysis comparing dose-intensive (DI-CIT) versus standard CIT for the frontline treatment of PMBCL. Standard approach (S-CIT) was defined as R-CHOP-21/CHO...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Michael R Cook Lacey S Williams Charles Scott Dorris Yutong Luo Kepher Makambi Kieron Dunleavy Source Type: research
